Richmond Pharmacology is excited to join the AHA Scientific Sessions 2026 in Chicago, USA, on 14–16 November 2026, hosted by the American Heart Association.

Bringing together global leaders in cardiovascular science, this premier event showcases groundbreaking research, clinical innovations, and collaborative strategies to advance heart health worldwide.

Representing Richmond Pharmacology

  • Dr Jörg Taubel, Chief Executive Officer

We look forward to connecting with attendees to discuss Richmond’s expertise in:

  • Novel therapies and clinical trial strategies for cardiovascular disease
  • Biomarker-driven approaches to improve trial efficiency
  • Regulatory pathways for emerging treatments
  • Patient-centric recruitment and engagement strategies
  • Collaboration between academia, industry, and regulators

Connect With Us

If you are attending AHA Scientific Sessions 2026 and would like to explore partnership or development opportunities email us at:

📧 fasteranswers@richmondpharmacology.com

Latest news

How Richmond Pharmacology Supports Sponsors Navigating ICH E6 (R3)

February 5, 2026
The updated ICH E6 (R3) guideline places greater emphasis on proportionality, risk-based oversight...
Read more

Events

Clinical Trials Innovation Programme

10 - 11 February 2026
Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.
View event